Skip to main content

Table 1 Demographics and clinical characteristics of study participants

From: Microglial activation in Parkinson’s disease using [18F]-FEPPA

 

Total (n = 52)

HC (n = 22)

PD (n = 30)

Age, mean (SD)

65.0 (7.70)

64.4 (8.06)

65.5 (7.54)

Gender (M:F)

33:19

11:11

22:8

TSPO genotype

27 HAB, 25 MAB

11 HAB, 11 MAB

16 HAB, 14 MAB

Handedness (R:L:both)

38:5:1

13:0:1

25:5:0

Years of education, mean (SD)

16.4 (3.25)

16.3 (3.00)

16.4 (3.40)

MoCA, median (range)

28 (26–30)

28 (26–30)

28 (26–30)

MMSE, median (range)

 

29.5 (27–30)

 

BDI II, median (range)

6 (0–23)

4.5 (0–16)

8 (0–23)

Symptom dominant side (R:L)

  

19:11

UPDRS III, median (range)

  

24 (4–45)

Duration of disease (years), median (range)

  

5 (2–15)

Total LEDD, mean (SD)

  

395.5 (483.21)

Amount injected (mCi), mean (SD)

4.9 (0.28)

4.8 (0.22)

5.0 (0.27)a

Mass injected (μg), mean (SD)

1.0 (0.70)

1.1 (0.83)

1.0 (0.59)

Specific radioactivity (mCi/μmol), mean (SD)

2670.8 (1559.56)

2707.8 (1626.74)

2643.6 (1536.00)

  1. Values are expressed as mean (SD) and as median (range) where applicable
  2. UPDRS-III, Unified Parkinson’s Disease Rating Scale III, MoCA Montreal Cognitive Assessment, BDI II Beck Depression Inventory II, MMSE Mini-Mental-State Examination, LEDD levodopa equivalent daily dose
  3. aSignificantly different